Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY · NASDAQ Global Market
-$0.61 today
Vol 0.65M · Avg 0.82M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:HRMY · Revenue to Net Income
Key Ratios
Analysis
$899.1M of revenue converted into $145.6M of net income for the selected period. Gross margin is 76.8% and net margin is 16.3%, showing how much revenue survives after costs and taxes. EPS is $2.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $868.5M +21.5% | $714.7M +22.8% | $582.0M +32.9% | $437.9M +43.4% | $305.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $198.3M +26.5% | $156.8M +29.3% | $121.2M +45.2% | $83.5M +50.4% | $55.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $670.1M +20.1% | $557.9M +21.1% | $460.8M +30.0% | $354.4M +41.8% | $249.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.2% -0.9pp | 78.1% -1.1pp | 79.2% -1.8pp | 80.9% -0.9pp | 81.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $189.6M +30.0% | $145.8M +91.7% | $76.1M +7.3% | $70.9M +133.4% | $30.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $272.0M +22.9% | $221.3M +14.8% | $192.7M +18.0% | $163.3M +23.7% | $132.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $461.6M +25.8% | $367.1M +36.6% | $268.8M +14.8% | $234.2M +44.2% | $162.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $25.3M +5.1% | $24.1M -1.0% | $24.4M +4.2% | $23.4M +24.1% | $18.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $255.0M +9.3% | $233.4M +5.4% | $221.5M +50.8% | $146.9M +82.5% | $80.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 29.4% -3.3pp | 32.7% -5.4pp | 38.1% +4.5pp | 33.5% +7.2pp | 26.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $208.5M +9.2% | $190.8M -0.6% | $192.0M +59.8% | $120.2M +37.3% | $87.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 24.0% -2.7pp | 26.7% -6.3pp | 33.0% +5.5pp | 27.4% -1.2pp | 28.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $21.9M +18.2% | $18.5M +25.9% | $14.7M +371.2% | $3.1M +1295.5% | $224.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $14.6M -16.3% | $17.5M -26.4% | $23.8M +26.4% | $18.8M -22.3% | $24.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.6M +574.3% | $978.0K +105.2% | -$18.6M -20.2% | -$15.5M +69.1% | -$50.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $215.1M +12.1% | $191.8M +10.6% | $173.4M +65.6% | $104.7M +179.7% | $37.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 24.8% -2.1pp | 26.8% -3.0pp | 29.8% +5.9pp | 23.9% +11.7pp | 12.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $56.4M +21.7% | $46.3M +4.0% | $44.5M +158.0% | -$76.8M -2812.2% | $2.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $158.7M +9.1% | $145.5M +12.9% | $128.9M -29.0% | $181.5M +424.5% | $34.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 18.3% -2.1pp | 20.4% -1.8pp | 22.1% -19.3pp | 41.4% +30.1pp | 11.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +7.8% | $3 +18.0% | $2 -29.3% | $3 +411.7% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +8.0% | $3 +17.8% | $2 -28.3% | $3 +412.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.5M +1.1% | $56.9M -4.3% | $59.5M +0.5% | $59.2M +2.9% | $57.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $58.5M +1.2% | $57.9M -4.1% | $60.4M -1.2% | $61.1M +3.2% | $59.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.53B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.20B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.09B
Nuvation Bio Inc.
NYSE:NUVB
$1.87B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.69B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.66B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Biohaven Ltd.
NYSE:BHVN
$1.42B
MannKind Corporation
NASDAQ:MNKD
$1.21B
Janux Therapeutics, Inc.
NASDAQ:JANX
$852.56M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HRMY generate?
Harmony Biosciences Holdings, Inc. (HRMY) reported $868.45M of revenue in fiscal 2025.
Is HRMY profitable?
Harmony Biosciences Holdings, Inc. (HRMY) reported $158.69M of net income, with a net margin of 18.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.